Indy without Lilly, the 500?
An Indiana University prof thinks Indianapolis should anticipate a future without Indianapolis Motor Speedway, and a potentially
reduced Eli Lilly and Co.
Health Care Businesses
Articles
Enzon Pharmaceuticals sells Indy drug plant; 100 local jobs safe
New Jersey-based Enzon Pharmaceuticals Inc. has sold its Indianapolis plant that manufactures specialty drugs in a deal that
could top $300 million. The buyer says that the operations, which employ about 100, will remain in the city.
Health care reform will go on regardless of federal government
Massachusetts’ election of a Republican senator has put health reform legislation on life support. But for the health
care industry, reform is a reality that isn’t going to die.
Bioanalytical Systems’ CEO announces retirement
Struggling West Lafayette life science contract research firm will search nationally for a new permanent leader.
Lilly shares trade down after fourth-quarter profits falls
Analysts worry about dive in already paltry sales of new blood thinner Effient
Accounting charge dents Zimmer’s fourth-quarter profits
But excluding special charges, Warsaw-based orthopedic implant maker grows profits 5 percent, easily beating expectations
of Wall
Street.
Express Scripts to add 182 pharmacy jobs by 2012
Drug distribution firm that acquired former WellPoint subsidiary plans to consolidate specialty pharmacy work at local
airport facility.
Lilly shares get boost from OK of rival’s drug
Shares of Lilly and partner Amylin rose on hopes that their new version of Byetta will be approved following U.S. regulators’
clearance of a similar drug.
Medical imaging supplier moves to Indianapolis
Associated X-Ray Services relocates headquarters from South Bend to Indianapolis and also announces the company has changed
its name to AXS Imaging.
Biotech firm plans $28M Greenwood plant
Greenwood pharmaceutical firm Elona Biotechnologies plans to build a $28 million production facility and create 70 jobs to
help develop a cheaper form of insulin that could gain significant market share.
FDA letters scold Lilly, others over marketing materials
The letter to Indianapolis-based Lilly cites a print advertisement for the antidepressant Cymbalta that did not adequately
display information about the drug’s side effects.
Roche taps new local CEO
Roche Diagnostics named a new CEO for its North American operations Tuesday to replace Michael Tillmann, who resigned on Friday.
Tillmann out as Roche Diagnostics CEO
The management change comes as the Indianapolis company’s diabetes market share has been sliding. Roche says successor will
be named “shortly.”
Hill-Rom hires new CEO
John J. Greisch was most recently president of international operations at Baxter International Inc.
FDA cancels meeting to review Lilly’s Cymbalta
The agency said the meeting was canceled “to allow time for the FDA to review new information” about a proposed new use for
the drug.
Health care software firm RealMed regains momentum
RealMed enjoys a nearly 99-percent renewal rate among its current customers and attracted 4,000 new doctors
in 2009. Employment at the company is rising after a steady decline.
Corporations bet on insiders to bend reform
Indianapolis health care heavyweights are among those spending $635 million, employing 166 former aides to key congressional
leaders and committees in health reform process.
To keep sales force busy, Lilly takes on new drug
Eli Lilly and Co. has bought the rights to co-market a new cholesterol-fighting drug in the U.S., giving it a third heart drug for sales personnel
to push.
Health care industry braces for reform
Congress is on the cusp of transforming health insurance—if it can pass a health reform bill that was losing popularity
late in the year.
Setbacks in diabetes market batter Roche
Roche Diagnostics Corp., once the darling of the U.S. diabetes-device market, is now licking its wounds. And
it’s mulling whether to keep fighting on all fronts or to pull back.